Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Elsea, Collin R ^a   Roberts, Daniel A ^a   Druker, Brian J ^a,b   Wood, Lisa J ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; AUTACOID; CYTOKINE; PRIMER DNA; TAXOID;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; LEWIS CARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; MACROPHAGE; METABOLISM; NUCLEOTIDE SEQUENCE;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CYTOKINES; DNA PRIMERS; DOXORUBICIN; ENZYME ACTIVATION; ETOPOSIDE; FLUOROURACIL; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TAXOIDS;

EID: 48649086299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002355     Document Type: Article

References (54)

1. Janicki-Deverts D, Cohen S, Doyle WJ, Turner RB, Treanor JJ (2007) Infection-induced proinflammatory cytokines are associated with decreases in positive affect, but not increases in negative affect. Brain Behav Immun 21: 301-307.
2. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, et al. (2004) Production ofpro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 34: 1289-1297.
3. Huang Y, Henry CJ, Danizer R, Johnson RW, Godbout JP (2007) Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging.
4. Teeling JL, Felton LM, Deacon RM, Cunningham C, Rawlins JN, et al. (2007) Sub-pyrogenic systemic inflammation impacts on brain and behavior, independent of cytokines. Brain Behav Immun.
5. Willette AA, Lubach GR, Coe CL (2007) Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey. Brain Behav Immun.
6. Harden LM, du Plessis I, Poole S, Laburn HP (2006) Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol Behav 89: 146-155.
7. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070-4077.
8. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, et al. (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279: 1453-1461.
9. Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR (2006) Cancer chemotherapy-related symptoms: evidence to suggest a role for dproinflammatory cytokines. Oncol Nurs Forum 33: 535-542.
10. Boldt S, Weidle UH, Kolch W (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838.
11. Saleem A, Datta R, Yuan ZM, Kharbanda S, Kufe D (1995) Involvement of stress-activated protein kinase in the cellular response to 1-heta-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ 6: 1651-1658.
12. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, et al. (1996) Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79.
13. Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, et al. (1996) The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6: 606-613.
14. Olson JM, Hallahan AR (2004) p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10: 125-129.
15. Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, et al. (2006) The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Biological Research for Nursing. pp 7.
16. Bryniarski K, Ptak M, Ptak W (1996) The in vivo and in vitro effects of an alkylating agent, mechlorethamine, on IL-6 production in mice and the role of macrophages. Immunopharmacology 34: 73-78.
17. de Vries P, Singer JW (2000) Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents. Exp Hematol 28: 916-923.
18. Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES (2003) Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 52: 463-472.
19. Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289: F166-174.
20. Wang LC, Woon ST, Baguley BC, Ching LM (2006) Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res 16: 1-14.
21. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110: 835-842.
22. Moos PJ, Fitzpatrick FA (1998) Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A 95: 3896-3901.
23. Burkhart CA, Berman JW, Swindell CS, Horwitz SB (1994) Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res 54: 5779-5782.
24. Borut BSPF, Andersen OKB, Bogdan PR, Villigerd PM, Arendt-Nielson L (2004) Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 107: 7-15.
25. Manthey CL, Qureshi N, Stutz PL, Vogel SN (1993) Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J Exp Med 178: 695-702.
26. Moos PJ, Muskardin DT, Fitzpatrick FA (1999) Effect of taxol and taxolere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol 162: 467-473.
27. White CM, Martin BK, Lee LF, Haskill JS, Ting JP (1998) Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 46: 104-112.
28. Zaks-Zilherman M, Zaks TZ, Vogel SN (2001) Induction or proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 15: 156-165.
29. Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248: 370-372.
30. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A (2001) The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31: 2448-2457.
31. Muhl H, Nold M, Chang JH, Frank S, Eberhardt W, et al. (1999) Expression and release of chemokines associated with apoptotic cell death in human promonocytic U937 cells and peripheral blood mononuclear cells. Eur J Immunol 29: 3225-3235.
32. Christensen LV, Donegan SJ (1992) Preliminary observations on oral blood flow. J Oral Rehabil 19: 39-47.
33. Shishodia. S, Sodhi A, Shrivastava A (1997) Cisplatin-induced activation of murine bone marrow-derived macrophages require protein tyrosine phosphorylation. Int J Immunopharmacol 19: 683-690.
34. Shishodia S, Shrivastava A, Sodhi A (1998) Protein kinase C: a potential pathway of macrophage activation with cisplatin. Immunol Lett 61: 179-186.
35. Sodhi A, Pai K (1992) Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers. Immunol Lett 34: 183-188.
36. Suresh A, Sodhi A (1991) Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide. Immurnol Lett 30: 93-100.
37. Pogrebniak HW, Matthews W, Pass HI (1991) Chemotherapy amplifies production of tumor necrosis factor. Surgery 110: 231-237.
38. Singh RK, Sodhi A (1991) Effect of TNF priming of murine peritoneal macrophages on their activation to a tumoricidal state. Immunol Lett 28: 127-133.
39. Singh RK, Sodhi A, Singh SM (1991) Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages. Nat Immun Cell Growth Regul 10: 105-116.
40. Schindler JF, Monahan JB, Smith WG (2007) p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 86: 800-811.
41. Peifer C, Wagner G, Laufer S (2006) New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem 6: 113-149.
42. Goldstein DM, Gabriel T (2005) Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 5: 1017-1029.
43. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al. (2007) p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11: 191-205.
44. Berthiaume JM, Wallace KB (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23: 15-25.
45. Losa J, Cobo C, Viniegra J, Lobo V, Cajal S, et al. (2003) Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22: 3998-4006.
46. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R (2003) p38 Mitogen-Activated Protein Kinas Mediates Cell Death and p21-Activated Kinase Mediates Cell Survival during Chemotherapeutic Drug-induced Mitotic Arrest. Mol Biol Cell 14: 2071-2087.
47. Boldt S, Weidle UH, Kolch W (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838.
48. Ma SF, Nishikawa M, Hyoudou K, Takahashi R, Ikemura M, et al. (2007) Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney Int 72: 1474-1482.
49. Thompson D, Greco A, Miller A, Srinivas N, Igwenezue K, et al. (1995) A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clinical Pharmacology & Therapeutics 57: 499-507.
50. Jacobsen S, Petersen IS, Danneskiold-Samsoe B (1993) Clinical features in patients with chronic muscle pain-with special reference to fibromyalgia. Scand J Rheumatol 22: 69-76.
51. Hempel G, Flege S, Wurthwein G, Boos J (2002) Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology 49: 133-141.
52. Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, et al. (2004) Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72: 403-409.
53. Morse SM, Shaw G, Larner SF (2006) Concurrent mRNA and protein extraction from the same experimental sample using a commercially available column-based RNA preparation kit. Bio Techniques 40: 54-58.
54. Bertram J, Janik P (1980) Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Letters 11: 63-73.